Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirabrutinib maintenance therapy for primary intraocular lymphoma in complete remission
jRCT2031200383Phase 2Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary intraocular lymphoma (PIOL) comparing Tirabrutinib arm with Placebo arm (2 arms). Primary endpoint: Relapse-free survival. Started Apr 2021; status: active, not recruiting.
02
Drugs
tirabrutinib
03
Conditions
primary intraocular lymphoma (PIOL)
Beyond the preview
Go deeper on jRCT2031200383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200383.